Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VIP943 |
Synonyms | |
Therapy Description |
VIP943 is an antibody-drug conjugate (ADC) targeting IL3RA (CD123) with a KSP inhibitor payload, which potentially inhibits tumor growth (Blood (2022) 140 (Supplement 1): 5955–5956). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VIP943 | VIP 943|VIP-943 | VIP943 is an antibody-drug conjugate (ADC) targeting IL3RA (CD123) with a KSP inhibitor payload, which potentially inhibits tumor growth (Blood (2022) 140 (Supplement 1): 5955–5956). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06034275 | Phase I | VIP943 | Study of VIP943 in Subjects With Advanced CD123 pos Hematologic Malignancies | Recruiting | USA | 0 |